Roche CEO outlines new R&D strategy after years of late-stage trial failures

New Roche CEO Thomas Schi­neck­er is im­ple­ment­ing a re­fined R&D strat­e­gy for the sprawl­ing Swiss con­glom­er­ate in the wake of sev­er­al re­cent late-stage fail­ures.

The new goals aim to en­sure pipeline pro­grams can move more ef­fi­cient­ly from ear­ly-stage to late-stage, while the com­pa­ny al­so hunts for deals on drugs al­ready be­ing test­ed in hu­man tri­als, Schi­neck­er said Mon­day dur­ing Roche’s Phar­ma Day in Lon­don.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.